Author name:
عمار حسن عبد الهادي القزاز
Supervisor name:
انوار فاروق مسلم
Key words:
- prostatic carcinoma
- DPP-4
- ROC
- PON-1
- Irisin
- Omentin
- PSA
- adipokines
- Prostate cancer
Abstract:
Prostate cancer is a type of cancer that occurs when abnormal cells grow in the prostate. Prostate cancer is a serious condition with a low overall survival rate, mainly due to late diagnosis. However, ongoing research and medical advances offer hope for improved outcomes in the future. The current study aims to evaluate the role of hormonal therapy and chemotherapy on some biochemical parameters for patients diagnosed with prostate cancer. Moreover, the study conducted a comparative analysis between the effects of body mass index after hormonal treatment on these biochemical parameters. During the period from November 2022 to May 2023, samples were collected from patients who have previously been diagnosed with prostate cancer and had a review history at the Imam Hussein Center for Oncology and Hematology (Amal Building), and at the Imam Hussein Medical City and the Imam Hassan Teaching Hospital in Holy Karbala. Finally, in the Oncology Teaching Hospital in Baghdad Medical City. 120 people participated in this study. The individuals were divided into 3 groups: The first group represents the healthy control group (G1), which consisted of 30 individuals. The second group, which represents prostate cancer patients undergoing chemotherapy (G2), consisted of 30 patients, and the third group represents prostate cancer patients undergoing hormonal therapy (G3), consisted of 60 patients. The third group was divided according to BMI into two groups: BMI (G3A) > 25kg/m2 30 patients, BMI (G3B) < 25 kg/m2pstients. The age group was more than 45 years was selected for all the mentioned categories. Using a carefully designed questionnaire form that included a comprehensive history and unique information about each patient, an in-person interview was conducted with each patient. Patients with diabetes, rheumatoid arthritis, heart disease, and renal failure were excluded from this study. The samples were experimentally tested for some biochemical parameters : Prostate-Specific Antigen (PSA), Dipeptidyl Peptidase IV (DPP-4),Omentin, Fibroblast Growth Factor 23(FGF-23), Irisin, Paraoxonase1(PON1), Retinol Binding Protein4 (RBP-4), Vitamin A, Vitamin D. The present study has shown interesting results, a significant decrease in the parameters under study, including Omentin, Irisin, in addition to Vitamins D, when compared the patient group with the control group(G1), while there was a significant increase in the other biochemical parameters, including retinol carrier, PON-1 enzyme, DPP-4, FGF-23, and finally the prostate-specific antigen, when compared with the control group. Additionally, there was a clear effect of body mass index, especially weight gain, on these parameters, in addition to the response to hormonal treatment. The Receiver Operating Characteristic (ROC) curve analysis for FGF-23, Omentin, DPP-4, Vitamin D and A across all groups reveals an impressive area under the curve (AUC) values. These suggests a high level of accuracy in distinguishing between the groups.On the other hand AUC value of PSA, Irisin, PON-1, has a good diagnostic value. Finally, AUC value of RBP-4 has a less diagnostic value. These results indicate that the studied parameters were diagnostic biochemical for prostate cancer along with the basic indicators, in addition to the extent of patients’ response to chemotherapy and hormone therapy. However, more research is needed to fully understand its mechanism of action and evaluate its effectiveness clinically.
